Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin

Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post-acute care facilities on dissemination

(2010) F. Perez et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Molecular Epidemiology of KPC-Producing Klebsiella pneumoniae Isolates in the United States: Clonal Expansion of Multilocus Sequence Type 258

(2009) B. Kitchel et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Infection with PanresistantKlebsiella pneumoniae:A Report of 2 Cases and a Brief Review of the Literature

(2009) Azza Elemam et al.   CLINICAL INFECTIOUS DISEASES

Success of an Infection Control Program to Reduce the Spread of Carbapenem-Resistant Klebsiella pneumoniae

(2009) Sandeep Kochar et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY

Clonal Dissemination of Klebsiella pneumoniae Carbapenemase KPC-3 in Long Beach, California

(2009) J. Le et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Pharmacokinetic Considerations regarding Tigecycline for Multidrug-Resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii Urosepsis

(2009) B. A. Cunha   JOURNAL OF CLINICAL MICROBIOLOGY

The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria

(2009) Patrice Nordmann et al.   LANCET INFECTIOUS DISEASES

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review

(2009) Matthew E Falagas et al.   LANCET INFECTIOUS DISEASES

Streptococcus pneumoniae Coinfection Is Correlated with the Severity of H1N1 Pandemic Influenza

(2009) Gustavo Palacios et al.   PLoS One

Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies

(2008) Theodoros Kelesidis et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae

(2008) K. Vasilev et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY